Plagued by production issues, Pfizer aims to shift EpiPen work to Mylan-Upjohn merger
Mylans EpiPen has had a troubled few years—to say the least—with federal prosecutors knocking at the door and shortages plaguing production. Now, with Mylan and Pfizers generic business Upjohn working on a merger, a new EpiPen manufacturer could be in the cards. Mylan and Pfizer are in talks to move EpiPens production to the new merged generics company, which is expected to take flight in mid-2020. A spokeswoman for Pfizer, which manufactures the drug under its Meridian Medical Technologies unit, said talks are ongoing and terms have yet to be finalized.
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
